Monte Rosa Therapeutics Inc (GLUE)
Healthcare
Biotechnology
—
16.50 $
-27.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Monte Rosa Therapeutics Inc (GLUE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -23 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -6.2 | -23 | -59 | -92 | -44 | 42 | -23 | |
| 0.1 | 0.5 | 2.1 | 3.7 | 6.2 | 8.1 | 8.4 | |
| 0.0 | 0.4 | 5.2 | 12 | 17 | 18 | 19 | |
| -3.3 | 8.0 | 5.2 | 12 | – | – | – | |
| 1.8 | 4.3 | 6.3 | -2.1 | 72 | 91 | -9.2 | |
| 1.4 | 3.4 | 9.7 | 13 | 19 | 4.0 | 4.7 | |
| -1.4 | -3.4 | -9.7 | -219 | 89 | -44 | -102 | |
| 0.0 | -0.4 | 378 | 21 | -0.1 | -0.6 | -0.4 | |
| 9.0 | – | – | – | – | – | – | |
| 15 | 60 | 378 | 20 | 27 | 99 | 30 | |
| 7.4 | 32 | 309 | -291 | 72 | 96 | -94 | |
| -7.6 | -26 | -69 | -105 | -63 | 38 | -27 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.